| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 11, 2025 |
| Accession Number: | 0001213900-25-021251 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2025 | $75.00 | Overweight | Piper Sandler |
| 11/13/2025 | $45.00 | Buy | Jefferies |
| 10/27/2025 | $60.00 | Buy | Guggenheim |
| 10/13/2025 | $48.00 | Overweight | Barclays |
| 5/22/2025 | $44.00 | Buy | BTIG Research |
| 2/4/2025 | $20.00 | Outperform | Wolfe Research |
| 10/11/2024 | $49.00 | Buy | Stifel |
| 10/7/2024 | $45.00 | Buy | H.C. Wainwright |
SCHEDULE 13G - Oruka Therapeutics, Inc. (0000907654) (Subject)
144 - Oruka Therapeutics, Inc. (0000907654) (Subject)
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
Piper Sandler initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $75.00
Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00
Guggenheim initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $60.00
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Date: Thursday, February 12th, 2026Presentation Time: 10:30AM ET TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3rd, 2026Presentation Time: 1:10PM ET UBS Biotech Summit MiamiDate: Monday March 9th, 2026 Jefferies Biotech on the Beach SummitDate: March 10th, 2026 Leerink
ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announc
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026. Presentation DetailsDate: Thursday, January 15th, 2026Time: 9:00 AM PT A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka Therapeutics Oruka
MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan
SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)